PTC Therapeutics director Schmertzler sells $1.35m shares
Corcept Therapeutics' President Roberto Vieira sold 296 shares of the company's stock on September 16, 2026. Each share was sold for $100.82, resulting in a total of $29,842. The stock has increased by 224% over the past six months, driven by improving fundamentals. This transaction was part of a pre-planned 10b5-1 trading plan Vieira adopted in June 2026.
After this sale, he still owns 3,946 shares, including shares from unvested restricted stock awards that are set to vest in a year, provided he meets certain requirements. Despite some analysts suggesting the stock is overvalued, the company has a "GOOD" financial health score. Recently, Corcept Therapeutics reported strong second-quarter 2026 earnings, with revenue up 32% year-over-year.
The company has also raised its revenue outlook for the year. Analysts have raised their price targets for the stock, reflecting continued growth in their core business.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
